CELC
Celcuity Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Celcuity Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
No other changes.
No other changes.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.24%
vs ±7.9% implied · ×0.79
shaded = implied · ▲▼ = realized
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Celcuity Inc.'s 2 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Celcuity Inc.'s 2 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Celcuity Inc.
68.86
−0.86 · −1.23%
Bull1
Bear2
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $828.2M | 13.53% | 0.00% |
| venBio Select Advisor | $355.7M | 5.81% | −4.90% |
| RTW | $345.8M | 5.65% | +8.73% |
| Perceptive | $334.5M | 5.46% | +2.24% |
| BlackRockindex-like | $315.8M | 5.16% | +11.33% |
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $828.2M | 13.53% | 0.00% |
| venBio Select Advisor | $355.7M | 5.81% | −4.90% |
| RTW | $345.8M | 5.65% | +8.73% |
| Perceptive | $334.5M | 5.46% | +2.24% |
| BlackRockindex-like | $315.8M | 5.16% | +11.33% |
Expected move
Inputs8Q avg ±4.4%·×2.32·rich
straddle ±14.0%
spot 69.72exp Nov 20ATM strike 70ATM straddle 11.45IV 95%